Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
63 results about "Crth2 antagonist" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
CRTH2 antagonists provide a potentially convenient oral treatment for severe asthma. The results of long-term studies in severe asthma focusing on exacerbations will dictate whether these drugs have sufficient efficacy to be approved by drug regulatory authorities for the treatment of asthma.
Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin
Topically applicable pharmaceutical / dermatological / cosmetic compositions well suited for the therapeutic treatment or care of sensitive human skin, hair, mucous membranes, nails and / or the scalp, in particular for reducing or avoiding the skin-irritant side effects of a variety of bioactive agents, for example the alpha -hydroxy acids, comprise a therapeutically / cosmetically effective amount of at least one calcitonin gene related peptide ("CGRP") antagonist, e.g., CGRP 8-37 or an anti-CGRP antibody.
Owner:LOREAL SA
Methods of administering/dosing CD2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
InactiveUS20030068320A1Symptoms improvedGood curative effectAntipyreticAnalgesicsSide effectAutoimmune disease
The present invention provides compositions for the prevention or treatment of an autoimmune disorder or an inflammatory disorder in a subject comprising one or more CD2 antagonists. In particular, the invention provides methods for preventing or treating an autoimmune disorder or an inflammatory disorder in a subject comprising administering one or more CD2 binding molecules to said subject. The present invention provides doses of CD2 binding molecules and methods of administration that result in improved efficacy, while avoiding or reducing the adverse or unwanted side effects associated with the administration of an agent that induces the depletion of peripheral blood lymphocytes.
Owner:MEDIMMUNE LLC
Pharmaceutical composition for intranasal administration containing a CGRP antagonist
Owner:BOEHRINGER INGELHEIM PHARM KG
CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
The present invention provides a method for the treatment of allergic and inflammatory diseases or conditions by administering a compound of Formula (I). The invention provides a method of treatment that is particularly suited for patients with a high degree of airway eosinophilia in contrast to those with a lower degree of airway eosinophilia. The invention also provides a method of treatment that is particularly suited for patients with a high atopic status in contrast to those patients with a lower atopic status.
Owner:ATOPIX THERAPEUTICS
Methods of administering/dosing CD2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
InactiveUS20070025990A1Symptoms improvedGood curative effectAntipyreticAnalgesicsSide effectAutoimmune disease
The present invention provides compositions for the prevention or treatment of an autoimmune disorder or an inflammatory disorder in a subject comprising one or more CD2 antagonists. In particular, the invention provides methods for preventing or treating an autoimmune disorder or an inflammatory disorder in a subject comprising administering one or more CD2 binding molecules to said subject. The present invention provides doses of CD2 binding molecules and methods of administration that result in improved efficacy, while avoiding or reducing the adverse or unwanted side effects associated with the administration of an agent that induces the depletion of peripheral blood lymphocytes.
Owner:MEDIMMUNE LLC
Methods of preventing or treating T cell malignancies by administering CD2 antagonists
InactiveUS20040265315A1Good curative effectImprove survivalImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAntigenMedicine
The present invention encompasses the use of a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof as a single agent therapy for the prevention, treatment, management, or amelioration of cancer, particularly a T-cell malignancy, or one or more symptoms thereof. The present invention also encompasses the use of a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof in amounts effective to prevent, treat, manage, or ameliorate cancer, particularly a T-cell malignancy, or one or more symptoms thereof
Owner:MEDIMMUNE LLC
Pharmaceutical formulations comprising ccr3 antagonists
The present invention relates to pharmaceutical compositions containing one or more compounds of formula 1whereinR1 is H, C1-6-alkyl, C0-4-alkyl-C3-6-cycloalkyl, C1-6-haloalkyl;R2 is H, C1-6-alkyl;X is an anion selected from the group consisting of chloride or ½ dibenzoyltartratej is 1 or 2.processes for the preparation thereof, and their use to treat diseases connected with the CCR3 receptor
Owner:ALKAHEST INC
Ccr2 antagonists for treatment of fibrosis
Anti-MCP-1 / CCR2 antagonist therapy is provided for the control or reversal of fibrosis related diseases, including, e.g., but not limited to MCP-1 / CCR2 antagonist therapy for the modulation of profibrotic markers associated with fibrotic processes including collagen matrix deposition and alveolar collapse.
Owner:CENTOCOR ORTHO BIOTECH
Use of CRTH2 Antagonist Compounds
InactiveUS20110124683A1Reduced stateReduce the amount requiredBiocideAnimal repellantsAllergic conditionPulse therapy
The invention relates to compounds of general formula (I):wherein R1, R2, R3, R4 and R5 are as defined hereinfor the treatment of allergic conditions, wherein the treatment is by pulsed therapy which comprises a first period during which the compound is administered to the patient and a second period of at least seven days during which the compound is administered to the patient in a reduced amount. The invention also relates to compounds of general formula (I) for desensitizing the immune system of a subject to allergens, thus preventing or reducing the symptoms of allergic conditions such as allergic asthma, allergic rhinitis, or atopic dermatitis.
Owner:ATOPIX THERAPEUTICS
Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders
Owner:AXIKIN PHARMA +1
Polycyclic acid compounds useful as crth2 antagonists and antiallergic agents
InactiveCN101636386AHas CRTH2 binding activityOrganic active ingredientsSenses disorderAllergic dermatitisDisease
The present invention relates to a novel compound or a salt thereof, which is useful as a CRTH2 antagonist, especially as a medicament for disorder that participates eosinophil, for example, allergic disorder such as asthma, allergic rhinitis, allergic dermatitis, conjunctival inflammation, hives, eosinophilic bronchitis, food allergy, inflammation of the nasal sinuses, multiple sclerosis, angiitis, or chronic obstructive pulmonary disease (COPD) and the like.
Owner:ASTELLAS PHARMA INC
Substituted piperazines as cb1 antagonists
InactiveUS20100286160A1Lower Level RequirementsOrganic active ingredientsNervous disorderSmoking cessationAntagonist
Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.
Owner:INTERVET INC
Quinoline Derivatives as CRTH2 Antagonists
Owner:PFIZER INC
Substituted piperazines as cb1 antagonists
InactiveUS20100249144A1Lower Level RequirementsAntibacterial agentsOrganic active ingredientsDiseaseGastrointestinal disorder
Compounds of Formula (I) or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.
Owner:INTERVET INC
Soluble interleukin-1 receptor accessory molecule
Owner:HUMAN GENOME SCI INC
Salts with CRTH2 antagonist activity
The potassium, sodium, ammonium, lysine, diethylamine, tromethamine (TRIS), piperazine, ethylenediamine and ethanolamine salt of a compound of general formula (I): wherein R<1> is halo or cyano; R<2> is C1-C4 alkyl; and R<3> is quinolyl or phenyl substituted with methane sulfonyl; can be synthesised by a novel method and are substantially more soluble than the parent free acids in a range of solvents.
Owner:OXAGEN
Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis
Disclosed are methods and compositions for preventing, treating, or ameliorating eosinophilic esophagitis (EoE) in an individual, comprising administering to the individual a therapeutically effective amount of at least one CRTH2 antagonist or a pharmaceutically acceptable salt thereof and at least one proton pump inhibitor (PPI) or a pharmaceutically acceptable salt thereof. Also disclosed are compositions comprising at least one CRTH2 antagonist or a pharmaceutically acceptable salt thereof and at least one proton pump inhibitor or a pharmaceutically acceptable salt thereof.
Owner:ATOPIX THERAPEUTICS
Methods of preventing or treating t cell malignancies by administering Anti-cd2 antagonists
InactiveUS20110280868A1Good curative effectImprove survivalImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAntigenAntigen Binding Fragment
Owner:UNITED STATES OF AMERICA +1
Use of cd23 antagonists for the treatment of neoplastic disorders
InactiveUS20080171056A1Efficient administrationImprove efficiencyImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsDiseaseB cell
Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).
Owner:BIOGEN MA INC
Use of selected CGRP antagonists for combating menopausal hot flushes
Owner:RUDOLF KLAUS +8
Compounds having CRTH2 antagonist activity
Compounds of general formula (I) wherein R is phenyl optionally substituted with one or more halo substituents ; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.
Owner:OXAGEN
Pyrazole compounds as CRTH2 antagonists
InactiveCN102884051AOrganic active ingredientsSenses disorderCombinatorial chemistryPharmaceutical formulation
The present invention relates to pyrazole compounds of formula (I) and pharmaceutically acceptable salts thereof having CRTH2-activity, wherein W, L1, L2, X, L3, Y, R1 and R2 are as defined in the specification and claims, to their use as medicaments and to pharmaceutical formulations, containing said compounds or containing a combination of said compounds with one or more active substances.
Owner:GB007 INC
Substituted aminoquinazoline compounds as a2a antagonist
The present invention is directed to compounds of generic formula (I): or pharmaceutically acceptable salts thereof that are believed to be useful as an A2A-receptor antagonist. The invention is further directed to methods of treating a patient (preferably a human) for diseases or disorders in which the A2A-receptor is involved. The invention further involves use of the compounds as an A2A-receptor antagonist and / or inhibitor for the preparation of a medicament for the treatment and / or prevention of diseases associated with inhibiting the receptor, which includes central nervous system disorders such as Parkinson's disease. The invention is also directed to pharmaceutical compositions which include an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases.
Owner:MERCK SHARP & DOHME LLC
Ccr-2 antagonists for treatment of neuropathic pain
The invention is directed to methods of treating neuropathic pain and other neuropathic diseases and conditions with CCR-2 antagonists and pharmaceutical composition containing CCR-2 antagonists.
Owner:MERCK SHARP & DOHME CORP
Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders
Owner:AXIKIN PHARMA
Methods of preventing or treating T cell malignancies by administering CD2 antagonists
The present invention includes the use of CD2 antagonists, preferably MEDI-507, its analogs, derivatives or antigen-binding fragments as a single agent therapy to prevent, treat, treat or ameliorate cancer, especially T-cell malignancies, or one of them or multiple symptoms. The present invention also includes the use of a CD2 antagonist, preferably MEDI-507, an analogue, derivative or antigen-binding fragment thereof in combination with other cancer treatments. The present invention also provides a pharmaceutical composition containing a CD2 antagonist, preferably MEDI-507, its analogue, derivative or antigen-binding fragment, and the amount of the contained CD2 antagonist can effectively prevent, treat, treat or improve cancer, especially T-cell malignancies, or one or more symptoms thereof.
Owner:IMMUNOMEDICS INC +1
Substituted piperazines as cb1 antagonists
InactiveCN101790521AOrganic active ingredientsNervous disorderGastrointestinal disorderCognitive diseases
Owner:INTERVET INT BV
Method for predicting a treatment response to a CRHR1 antagonist and/or a V1B antagonist in a patient with depressive and/or anxiety symptoms
ActiveUS10190168B2Microbiological testing/measurementHeterocyclic compound active ingredientsCorticotropin-releasing hormone receptorAVPR1B Gene
The present invention relates to a method for predicting a treatment response to a corticotropin releasing hormone receptor type 1 (CRHR1) antagonist and / or a vasopressin receptor 1B (V1B) antagonist in a patient with depressive and / or anxiety symptoms. The present invention furthermore relates to a V1B receptor antagonist and / or CRHR1 antagonist for use in the treatment of depressive symptoms and / or anxiety symptoms in a patient. Also, kits, diagnostic compositions, devices and microarrays allowing the determination of the presence or absence of at least one polymorphic variant in the AVPR1B gene in combination with the presence or absence of at least one polymorphic variant in the patient's genome excluding the AVPR1B gene in the nucleic acid sample are described.
Owner:MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN EV
Methods of inhibiting tumor growth using ttk antagonists
ActiveUS20110002923A1Reduced patient survivalHigh expressionOrganic active ingredientsPeptide/protein ingredientsTumor SampleOncology
The present invention relates to methods for treating TTK positive breast cancers or soft-tissue sarcomas in a mammalian subject by administering a therapeutically effective amount of a TTK antagonist. The invention also provides compositions comprising a TTK antagonist and a HER-2 antagonist, as well as methods of diagnosing a basal-like breast cancer and methods of determining the prognosis of a subject having a cancer by assessing expression of TTK in a tumor sample from a subject.
Owner:UNIV HEALTH NETWORK
Polycyclic acid compounds useful as crth2 antagonists and antiallergic agents
InactiveCN102442941AStrong CRTH2 antagonistic activitySenses disorderOrganic chemistryAllergic dermatitisDisease
Owner:ASTELLAS PHARMA INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com